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Surfactant proteinNeuregulin (NRG) stimulation of ErbB4 signaling is important for type II cell surfactant synthesis. ErbB4mayme-
diate gene expression via a non-canonical pathway involving enzymatic cleavage releasing its intracellular do-
main (4ICD) for nuclear trafﬁcking and gene regulation. The accepted model for release of 4ICD is consecutive
cleavage by Tumor necrosis factor alpha Converting Enzyme (TACE) and γ-secretase enzymes. Here, we show
that 4ICDmediates surfactant synthesis and its release by γ-secretase is not dependent on previous TACE cleav-
age.Weused siRNA to silence Presenilin-1 (PSEN-1) expression in amouse lung type II epithelial cell line (MLE12
cells), and both siRNA knockdown and chemical inhibition of TACE. Knockdown of PSEN-1 signiﬁcantly de-
creased baseline and NRG-stimulated surfactant phospholipid synthesis, expression of the surfactant proteins
SP-B and SP-C, as well as 4ICD levels, with no change in ErbB4 ectodomain shedding. Neither siRNA knockdown
nor chemical inhibition of TACE inhibited 4ICD release or surfactant synthesis. PSEN-1 cleavage of ErbB4 for non-
canonical signaling through 4ICD release does not require prior cleavage by TACE.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Respiratory distress syndrome (RDS), formerly known as hyaline
membrane disease, is a common problem in preterm infants born be-
fore 28 weeks. This disease is caused primarily by deﬁciency of pulmo-
nary surfactant in immature lungs and is more common the earlier the
infant is born [1]. Despite the beneﬁcial effects of prenatal glucocorti-
coids and postnatal surfactant replacement therapies, RDS remains
one of the signiﬁcant causes ofmorbidity andmortality in premature in-
fants [2,1]. Pulmonary surfactant is amixture of surface active phospho-
lipids and proteins (termed surfactant protein B (SP-B) and SP-C)which
is produced in alveolar type II epithelial cells [3]. The development of
surfactant synthesis is under multifactorial control, in which paracrine
mesenchyme-type II cell communication mechanisms play a central
role. We have shown that the growth factor Neuregulin (NRG-1),
which is secreted by ﬁbroblasts, and its target receptor ErbB4, which isSurfactant protein C; NRG-1,
ing enzyme; DSPC, Disaturated
versity, Boston, MA 02148, USA.
ritzkat@gmx.de (A. Ritzkat),
n.castellot@tufts.edu
ights reserved.expressed by type II cells, play a prominent role in stimulation of type
II cell maturation and surfactant synthesis [4,5]. NRG is expressed in
the midtrimester human fetal lung [6] and increases in fetal lung at
the onset of surfactant synthesis [7].
ErbB4 is a member of the ErbB receptor tyrosine kinase family,
which also includes the epidermal growth factor receptor, also called
ErbB1, ErbB2, and ErbB3 [8]. The ErbB receptors are transmembrane ty-
rosine kinase proteins and act as important regulators of cell prolifera-
tion and differentiation during fetal organ development including lung
development [9]. ErbB4 signal transduction is a complexprocess that in-
volves both canonical and non-canonical signaling pathways. Binding of
NRG to its extracellular ligand-binding site causes ErbB4 to form homo
or heterodimers with other ErbB receptors linked by disulﬁde bonds
in the extracellular domain [10]. These receptor dimers then undergo
auto phosphorylation on tyrosine residues within the intracellular do-
main. In the canonical signal pathway tyrosine phosphorylation acti-
vates signal cascades through speciﬁc intracellular signaling pathways
such as the phosphatidylinositol-3 (PI3) Kinase/Akt pathway to ulti-
mately inﬂuence gene expression [11]. However, within the ErbB fami-
ly, ErbB4 is unique in that it may undergo proteolytic processing to
initiate non-canonical signaling [12]. The accepted model for the non-
canonical pathway involves two sequential cleavage processes. The
ﬁrst step in this pathway is performed by a transmembrane
metalloprotease Tumor necrosis factor alpha Converting Enzyme
(TACE) which releases the ErbB4 ectodomain by a cleavage that
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released into the extracellular space and an 80 kDa membrane-
associated fragment that contains the ErbB4 transmembrane domain
and the entire cytoplasmic region, including the tyrosine kinase domain.
Ectodomain cleavage of ErbB4 in cells occurs at a low constitutive or
basal level [13] that can be increased by neuregulin or other ErbB4
ligands [14]. The ectodomain cleavage of ErbB4 is sensitive to
metalloprotease inhibitors [13] and does not occur in cells genetically
deﬁcient in TACE. The ErbB4m80 fragment (membrane associated frag-
ment) that remains following ectodomain cleavage is further processed
by γ-secretase that cleaves at the transmembrane domain to release a
soluble intracellular s80 fragment (4ICD) into the cytosol from which
it translocates to the nucleus in association with chaperone proteins
[14,15]. Gamma secretase is an enzyme complex which consists of 4
components: presenilin 1 (PSEN-1) or Presenilin 2 (PSEN-2), Nycastrin,
anterior pharynx defective-1 (APH-1) and the Presenilin-Enhancer 2.
PSEN-1 or PSEN-2 are the active enzymatic component; other compo-
nents behave as scaffolding molecules and essential cofactors [16–19].
Studies with transgenic mice show that PSEN-1 and PSEN-2 have func-
tionally distinct phenotypes in several organs including the lung
[20,21].
Nuclear localization of ErbB4 is the preferred mechanism of ErbB4
signaling in several regulatory processes during development [22]. The
accepted model for γ-secretase activity in ErbB4 processing is that
ectodomain cleavage by TACE is a prerequisite step [12]. In this study
we sought tomore speciﬁcally deﬁne the sequential interactive relation-
ship of PSEN-1 and TACE for ErbB4 processing controlling lung alveolar
type II cell surfactant production. Our focus on PSEN-1 was motivated
by the more severe developmental phenotype of alveolar maturation in
the PSEN-1 knockout mouse compared to the PSEN-2 knock out and
our previous work showing the importance of PSEN-1 signaling for
fetal type II cell maturation [22,23]. We studied the effect of PSEN-1
knockdown and TACE knockdown in MLE12 cells and evaluated the ef-
fects on ErbB4 cleavage in association with the expression of the SP-B
and SP-C mRNA and protein and synthesis of the major surfactant phos-
pholipid disaturated phosphatidylcholine (DSPC).
2. Methods and materials
2.1. Materials
Dulbecco's Modiﬁed Eagle's (DME) low glucose medium was pur-
chased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS)
was from BD Biosciences (Lot # ANB 18202A), L-glutamine, Pen/Strep
and an siRNA cocktail of three siRNA sequences targeting PSEN-1
(Psen 1Mss208049, Psen 1Mss208050, Psen 1Mss208051) were pur-
chased from Invitrogen (Carlsbad, CA). TACE inhibitor TAPI-1 was pur-
chased from Peptides International (Louisville, KY). siRNA cocktail of
three siRNA sequences targeting TACE, SilencerNegative Control scram-
bled siRNAand Silencer GAPDHsiRNAwere purchased fromAmbion (St
Louis, MO). Glass 100 mm cell culture dishes were purchased from
Pyrex/Corning (St Louis, MO). The murine lung epithelial cell line
MLE12 was purchased from the American Type Culture Collection
(Manassas, VA), Neuregulin 1βwas produced using an expression vec-
tor kindly provided by Kermit Carraway III (UC Davis, CA) and puriﬁed
by Dr. Ann Kane, Phoenix Laboratory (Tufts Medical Center, Boston,
MA). BCA Protein Assay Kit and RIPA buffer were obtained from
Pierce/Thermo Scientiﬁc (Logan, UT), protease inhibitor cocktail from
Sigma Aldrich. Invitrolon PVDF ﬁlter paper and NuPage 4–12% Bis-Tris
pre-cast gels (1.0mmX12wells)were obtained fromNovex/Invitrogen.
Tris-Glycine-SDS 10X running buffer, transfer buffer (10X Tris-buffered
saline washing buffer) and TBS-Tween-20 (10X) were from Boston Bio
Products (Ashland, MA). Methanol 100%, Kodak ﬁlm (X-OMAT Blue
XB) and Restore Plus Western Blot Stripping Buffer were from Thermo
Fisher Scientiﬁc (Palm Beach, FL). Anti-Presenilin 1 N-terminal (1–65)
rabbit polyclonal antibody (cat#529591) was from Calbiochem/EMDMillipore (Billerica, MA). Anti-prosurfactant protein C (rabbit polyclonal
antibody, ab90716), anti-prosurfactant protein B (rabbit polyclonal anti-
body ab15011), monoclonal antibody to beta actin (HRP conjugated,
cat# 20272), Anti-TACE antibody (rabbit polyclonal antibody, cat#
ab2051) were all from Abcam (Cambridge, MA). Peroxidase-conjugated
AfﬁnipureGoat Anti-Rabbit IgG (H+L), (111-035-144)was from Jackson
ImmunoResearch. Anti-ERBb4 antibody (cat# sc-283) was obtained from
Santa Cruz (Santa Cruz, CA). Chloroform (spectrophotometric grade) was
obtained from Sigma Aldrich (St Louis, MO). Methanol was from Fisher
Scientiﬁc; Silica gel H thin layer chromatography sheets were from
Analtech (Newark, DE). Osmium tetroxide 05500-1G, carbon tetrachlo-
ride and dipalmitoylphosphatidyl choline (P-5911) were from Sigma
Aldrich (St Louis, MO). Ultima-Gold scintillation ﬂuid was from Perkin
Elmer (Waltham, MA). For centrifugation we used a Beckman J-6 M.2.2. Cell culture
MLE12 cells were used as a model for type II alveolar epithelial
cells. MLE12 cells exhibit characteristics of alveolar type II cells, in-
cluding the expression of SP-B and SP-C and formation of microvilli
and multivesicular bodies. They have a strong response to fetal
ﬁbroblast-conditioned media (FCM) and NRG with increased DPSC
synthesis [7,24]. MLE-12 cells were grown in DMEM containing
10% FBS, 2% pen/strep and 2% L-glutamine. Media were changed
every second day.2.3. Transfection with siRNA
MLE12 cells were transfected with siRNA using the transfection re-
agent Dharmafect 2. To knock down presenilin 1, three pre-designed
Presenilin-1 siRNA sequences that target three different regions of
Presenilin mRNA were used. To knock down TACE we used a cocktail
of 3 siRNAs targeting the TACE gene. The protocol for transfection of
MLE12 cells was adapted from the manufacturer's guidelines; all steps
were done using RNAse-free pipette tips and RNase spray for
decontaminating the work area. MLE12 cells were plated into 6 well
plates. The transfection process was initiated when the cells were 30–
40% conﬂuent. 5 μl siRNA in 95 μl serum free DMEM/well and 1 μl trans-
fection reagent Dharmafect 2 in 99 μ serum free DMEM/well) were in-
cubated for 5 min at room temperature, then mixed and incubated for
20 min at room temperature. At the end of the incubation, 800 μl of an-
tibiotic freemedia was added to themixture. A total of 1mL of transfec-
tion media was added to each well of cells and allowed to incubate at
37 °C. After 48 h, the transfection medium was aspirated and replaced
with fresh transfection media prepared as described above. A second
transfection step was done in the same manner after 48 h from the
ﬁrst transfection and cultures continued for another 24 h resulting in a
total exposure time of 72 h. When transfecting the cells for the second
time the media were changed to serum free media, and some cells
were treated with NRG (3.3 nM) for 24 h. Each experiment included
the control conditions of scrambled siRNA and GAPDH siRNA. After 72
h of total exposure time, the MLE-12 cells in the 6-well plates were
harvested.2.4. Chemical blockade of TACE
MLE12 cells were plated in 6 well plates. When the cells were
50–60% conﬂuent they were ﬁrst treated for 24 h with the TACE in-
hibitor TAPI. In preliminary experiments increasing concentrations
(50 nM, 100 nM, 150 nM, 200 nM, 300 nM) were used to determine
the minimal effective dose. Thereafter cells were treated for 24 h with
200 nM TAPI alone, TAPI plus NRG, NRG only or media only. Cells
were then harvested.
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Cells were harvested by ﬁrst washing with PBS 3 times. 500 μl RIPA
buffer: protease inhibitor mixture (1:50) was added to each well
twice. Using a cell scraper, cells were scrapped off plates (on ice),
aspirated, incubated on ice for 60minwith vortexing every 10min, cen-
trifuged at maximum speed for 15 minutes and the supernatant trans-
ferred to new tubes and stored at −20 °C. Protein concentration in
each sample was determined in duplicate (BCA protein assay, Thermo
Scientiﬁc).2.6. Western blot analysis
The protein sampleswere heated at 70 °C for 10minwith sample re-
ducing buffer to denature the protein. Proteins were loaded into pre-
cast NuPage 4–12% Bis-Tris gels and separated by gel electrophoresis.
Subsequently the proteins were transferred to a PVDF membrane. The
membrane was blocked with 5% dry milk in TBST for 2 h at room tem-
perature or at 4 °C overnight. The blots were probed with primary
antibody against PSEN-1 or TACE, and then stripped and probed for
SP-B, SP-C and beta Actin. Primary antibodies were incubated overnight
at 4 °C and secondary antibodies were incubated for 2 h at room tem-
perature. Blots were developed using Western Lightning Plus ECL and
detected with a Kodak ﬁlm X-OMAT Blue XB. Densitometry was done
for all blots and beta actin was used as an internal control for protein
loading.2.7. Choline incorporation into DSPC
MLE12 cells were cultured and transfected in 24-well plates as de-
scribed above except that the cells were treated with 0.5 μCi/ml [3H]
choline for the ﬁnal 24 h of transfection. At the end of the 72 h of trans-
fection, the cells were harvested, the lysates sonicated and protein con-
centrations measured. DSPC was isolated by lipid extraction, osmium
tetroxide treatment and then liquid chromatography as we have de-
scribed [25,7]. The isolated DSPC samples were placed in scintillation
ﬂuid and DPMs counted using a beta scintillation counter. The results
were calculated as DPM per μg protein and presented as percentage of
the experimental speciﬁc control value.2.8. RT-PCR
Real-time PCR was used to determine the mRNA levels for PSEN-1,
SP-B (Sftpb) and SP-C (Sftpc). PSEN-1 primers: Forward sequence 5′
TCA/AGA/AAG/CGT/TGC/CAG/C 3′, Reverse sequence 5′ CGT/GGC/
GAA/GTA/GAA/CAC/GA 3′, Sftpb primers: Forward sequence 5′ AGG/
ATG/CCA/TGG/GCC/CT 3′, Reverse sequence 5′ TCA/GTG/TCC/TGT/
AGT/GGC/CAT/T 3′, Sftpc primers: Forward sequence 5′ CCA/CTG/GCA/
TCG/TTG/TGT/ATG 3′, Reverse sequence 5′GTA/GGT/TCC/TGG/AGC/
TGG/CTT/A 3′, all were purchased from Applied Biosystems (Woburn,
MA). The 50 μl reaction master mix contained 25 μl Taq polymerase,
1.25 μl Multiscribe and RNA inhibitor mix, 8 μMeach of forward and re-
verse primer, 5 μMprobe and 1 μg of RNA sample. Ampliﬁcation and de-
tection of speciﬁc products were done with the ABI PRISM 7900
sequence detection system from Applied Biosystems. The ampliﬁcation
protocol consisted of an initial denaturation and enzyme activation at
95 °C for 10 min, followed by 45 cycles at 95 °C for 15 s and 60 °C for
1 min. In order to normalize the PSEN-1 and Sftp levels, actin was used
as an internal control. Samples were run in triplicate. The differences
in the Ct values of the PSEN-1 siRNA transfected cells compared to the
cells transfectedwith a scrambled (scr) siRNA sequencewere expressed
as DDCT and presented as % of the controls (= scr siRNA). The message
levels of Sftpb and Sftpc were calculated accordingly.2.9. Conditioned media
MLE12 cells (3× 105)were plated and treated for 72 hwith siRNA or
TAPI as described above. Conditioned media was collected probed for
the presence of the shed ectodomain of ErbB4 using western blot
analysis.
2.10. Statistics
Statistical analysis was done using non-parametric ANOVA with
post-hoc analysis or two-tailed t-tests (Graph Pad Software, San
Diego, CA) as appropriate with a level of signiﬁcance of P = 0.05. All
data are expressed as Means ± SEM.
3. Results
3.1. PSEN-1 knockdown decreases SP-B and SP-C expression in MLE12 cells
To determine if PSEN-1 regulates SP-B and SP-C expression, we
down regulated PSEN-1 using siRNA in MLE12 cells and measured the
effect on SP-C and SP-B mRNA using qRT-PCR and protein levels
using western blot analysis. PSEN-1 mRNA was reduced to 38% ± 17
(mean±SE, n=8) compared to the scrambled control; PSEN-1 protein
was reduced to 50% ± 12 (mean ± SE, n = 5, p = 0.02) of the scram-
bled control (Fig. 1A). At this level of PSEN-1 knockdown, Sftpb mRNA
was reduced to 67% ± 11 (mean ± SE, n = 8) compared to the
scrambled control. The level of SP-B protein was reduced to 60% ± 9.7
(mean ± SE, n = 5, p = 0.01) of the scrambled control (Fig. 1B). Sftpc
mRNA was reduced to 57% ± 6 (mean ± SE, n = 8) compared to the
scrambled control. SP-C protein was decreased to 63% ± 4.2 (mean ±
SE, n = 5, p =0.017) in response to PSEN-1 protein knock down
(Fig. 1C). The speciﬁcity of PSEN-1 knockdown was checked by assaying
GAPDH protein, which showed no signiﬁcant decrease at the highest
level of PSEN-1 knockdown (data not shown here). These results suggest
that PSEN-1 is required for optimal SP-B and SP-C expression.
3.2. PSEN-1 knockdown suppresses the stimulatory effect of neuregulin on
SP-B and SP-C protein expression
Others and we have previously shown that NRG stimulates surfac-
tant production through the ErbB4 receptor [4,5]. To determine if
PSEN-1 down-regulation affects the stimulatory effect of NRG, we
knocked down PSEN-1 in MLE12 cells as described above and exposed
these cells to 3.3 nM NRG during the ﬁnal 24 hours. Western blot anal-
ysis of scrambled control cells treated with NRG showed signiﬁcantly
increased expression of SP-B and SP-C to 150.7 ± 9; 148%± 10 respec-
tively;means± SE, n=5, p=0.01 and p= 0.002, respectively (Fig. 2A
and B). PSEN-1 knockdown completely abrogated the stimulatory effect
of NRG on SP-B and SP-C protein levels (Fig. 2C and D). These data sug-
gest that the ability of NRG to up-regulate SP-B and SP-C is dependent
upon adequate PSEN-1 expression.
3.3. Release of the ErbB4 cytoplasmic fragment (4ICD) is decreased in
MLE12 cells treated with PSEN-1 siRNA
The ErbB4 cytoplasmic domain (4ICD) is thought to be important to
control gene expression of surfactant proteins. To determine if PSEN-1
regulates the level of 4ICD, we knocked down PSEN-1 in MLE12 cells
and measured 4ICD levels using Western blot analysis. Cells treated
with PSEN-1 siRNA showed signiﬁcantly decreased levels of the 4ICD
product (60% ± 2.5; mean ± SE, n = 5, p = 0.03) compared to SCR
siRNA treated cells. Control samples (SCR siRNA) treated with NRG
showed increased 4ICD levels (130% ± 8 of non-NRG treatment;
mean± SE, n = 5, p = 0.02). Thus, NRG up-regulated PSEN-1 process-
ing of ErbB4, increasing the level of the 4ICD fragment, but in PSEN-1
knock-down cells NRG did not increase the 4ICD fragment. (Fig. 3).
Fig. 1. Representative western blots and densitometry quantiﬁcation showing PSEN-1 knockdown inMLE12 cells and the effect on SP-B and SP-C protein levels. Densitometry results are
expressed as% of the scrambled (SCR) siRNA condition (controls). Bars aremeans±SEMof N=5 experiments. *=P b 0.05. (A) PSEN-1 knockdown inPSEN-1 siRNA treated cells, GAPDH
siRNA treated cells and SCR siRNA treated cells. Values are expressed as% of the SCR condition (controls). (B) SP-B expression in PSEN-1 siRNA,GAPDHsiRNAandSCR siRNA treatedMLE12
cells. (C) SP-C expression in PSEN-1 siRNA, GAPDH siRNA and SCR siRNA treated MLE12 cells.
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DSPC is themajor phospholipid component andmajor surface active
component of surfactant. We therefore assessed the effect of PSEN-1
knockdown on DSPC synthesis in MLE12 cells. Cells treated with
PSEN-1 siRNA showed signiﬁcantly decreasedDSPC synthesis compared
to scrambled siRNA treated samples (Fig. 4). NRG increased the level of
DSPC synthesis in SCR-treated cells, and this stimulatory effect was lost
following PSEN-1 knockdown (Fig. 4). These results indicate that PSEN-
1 acts to regulate baseline and NRG-induced DSPC synthesis in MLE12
cells, similar to its effect on SP-B and SP-C.
3.5. Release of the ErbB4 ectodomain is not changed in MLE12 cells treated
with PSEN-1 siRNA
To assess the effect of PSEN-1 on expression of the ErbB4 ectodomain
we collected conditioned media from cells treated with PSEN-1 siRNA.
Conditioned media from NRG-treated cells showed increased free
ErbB4 ectodomain levels compared to untreated cells. Conditioned
media from cells treated with PSEN-1 siRNA showed no change in the
levels of the ErbB4 ectodomain (96%± 5;mean± SE, n= 5) compared
to SCR siRNA treated cells. The free ErbB4 ectodomain level was
increased in SCR cells treated with NRG to 120% ± 8.3 (mean ± SE,
n = 5), and in PSEN-1 siRNA treated cells the level of the 120 kD
ErbB4 ectodomain was increased to 135% ± 5.2 (mean ± SE, n = 5)(Supplementary Fig. 1). These observations suggest that, in contrast to
its effect on levels of the 4ICD cytoplasmic domain, PSEN-1 has no de-
tectable effect on the release of the ErbB4 ectodomain.3.6. TACE knockdown does not affect SP-B and SP-C expression In MLE12
cells:
The necessary ﬁrst step in proteolytic processing of ErbB4 leading to
ultimate release of the 4ICD fragment and non-canonical ErbB4 signal-
ing is thought to be cleavage by TACE, a trans-membrane metallopro-
teinase. To determine if TACE activity is required for NRG stimulation
of surfactant production, we used siRNA to knock down TACE in
MLE12 cells and measured SP-B and SP-C expression levels by west-
ern blot analysis. TACE protein was reduced to 53% ± 3 (mean ± SE,
n = 4, p = 0.003) of the scrambled control (Fig. 5A). MLE12 cells
treated with TACE siRNA showed no change in SP-B and SP-C
(Fig. 5B). Furthermore, TACE knockdown did not inhibit the stimula-
tion of SP-B and SP-C by NRG. Cells treated with NRG showed higher
expression of SP-B and C in the SCR treatment condition (140.7%± 9,
120% ± 7 respectively; mean ± SE, n = 4; p = 0.02, p = 0.003
respectively) and this stimulatory effect appeared to be maintained
in TACE knockdown samples (Fig. 5C and D). These results indicate
that NRG stimulation of surfactant production is largely independent
of TACE activity in MLE12 cells.
Fig. 2. The effect of NRG on SP-B and SP-C protein expression inMLE12 cells following PSEN-1 knock down. (A) SP-B expression in SCR siRNA treatedMLE12 cells in the absence and pres-
ence of NRG. (B) SP-C expression in SCR siRNA treatedMLE12 cells in the absence and presence of NRG. (C) SP-B expression in PSEN-1 siRNA treatedMLE12 cells in the absence and pres-
ence of NRG. (D) SP-C expression in PSEN-1 siRNA treated MLE12 cells in the absence and presence of NRG. Bars are means ± SEM of N = 5 experiments. * = P b 0.05, ** = P b 0.005
compared to no NRG treatment.
Fig. 3.Representativewestern blots and densitometry quantiﬁcation showing the effect of
PSEN-1 knockdown on the level of free ErbB4 cytoplasmic domain (4ICD) at baseline and
following NRG treatment. Mean± SEM, N=5. *= P b 0.05 compared to SCR cells treated
with NRG.
Fig. 4. The effect of PSEN-1 knockdown on choline incorporation into DSPC. Bars show the
mean±SEMof [3H]-choline incorporated intoDSPC, expressed as disintigrations permin-
ute (DPM)permicrogramof protein × 103 inMLE12 cells treatedwith PSEN-1 siRNA com-
pared to SCR treated cells, in the absence or presence of NRG. *=P b 0.05 compared to SCR
with NRG; ** = P b 0.005 compared to SCR without NRG.
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Fig. 5. Representative western blot and densitometry quantiﬁcation of TACE knockdown in MLE12 cells and the effect on surfactant protein expression. (A) TACE knockdown in TACE
siRNA, GAPDH siRNA and SCR siRNA treated cells. Densitometry values were normalized to actin and compared to SCR siRNA treatment. Bars show mean ± SEM of N= 4 experiments.
(B) Representative western blots of SP-B and SP-C expression in TACE siRNA, GAPDH siRNA and SCR siRNA treatedMLE12 cells. (C)Western blots and densitometry of SP-B expression in
TACE siRNA and SCR siRNA treated cellswithout andwithNRG treatment. Densitometry valueswere normalized to actin and compared to the respective SCR value. Bars aremeans±SEM
of N= 4 experiments; * = P b 0.05. (D) Western blots and densitometry of SP-C expression in TACE siRNA and SCR siRNA treated cells without and with NRG treatment. Densitometry
values are normalized to the respective SCR value. Bars are means ± SEM of N = 4 experiments; ** = P b 0.005.
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cells treated with TACE siRNA
To assess the role of TACE in the release of both the ectodomain and
the 4ICD components of ErbB4, we measured the ectodomain level in
conditioned media and the 4ICD level in cell lysates following TACE
knockdown via siRNA. Western blot analysis of cells treated with
TACE siRNA showed no change in 4ICD levels compared to SCR treated
cells (98% ± 2.5 of SCR cells; mean ± SE, n = 4). NRG treatment in-
creased the level of 4ICD in both SCR treated and TACE siRNA treated
cells (130.6% ± 2.1, 150% ± 2.3, means ± SE, n = 4 respectively) com-
pared to untreated scrambled control cells (Fig. 6A). To further demon-
strate that TACE inhibition blocked proteolytic release of the ErbB4
ectodomain, conditioned medium from TACE siRNA treated cells was
collected after 24 h of treatment, and media assayed for presence of
the released ectodomain fragment of ErbB4. Western blot analysis of
the conditioned media from cells treated with TACE siRNA showed de-
creased ErbB4 ectodomain levels (40% ± 1.1; mean ± SE, n = 5, p =
0.003) compared to scrambled siRNA treated cells. NRG stimulated the
level of released ectodomain in scrambled siRNA treated cells
(150%±8.7, mean±SE, n=4, p= 0.0173) compared to cells not treat-
edwith NRG. The stimulatory effect of NRG on ectodomain sheddingwas
signiﬁcantly lost in TACE siRNA treated samples (Fig. 6B). These observa-
tions indicate that TACE speciﬁcally regulates ectodomain cleavage, but
not cytoplasmic cleavage regulated by PSEN-1 leading to 4ICD release,
contrary to current models of ErbB4 non-canonical signaling.
3.8. Chemical inhibition of TACE activity
To further validate the results obtained from TACE knockdown, we
used TAPI, a speciﬁc and well-characterized chemical inhibitor of TACEactivity. Dose–response experiments in MLE12 cells showed that 200
nM was sufﬁcient to reduce active TACE levels (measured by western
blot) to 30% ± 1.4 (mean ± SE, n = 4, p = 0.0004) compared to
media treated cells (Supplementary Fig. 2).3.9. TACE inhibition by TAPI does not affect SP-B, 4ICD expression
We conﬁrmed the absence of a role of TACE in ErbB4-mediated
regulation of SP-B by treating MLE12 cells with 200nM TAPI without
and with NRG. MLE12 cells treated with TAPI showed no change in
SP-B (99% ± 1.4, mean ± SE, n = 4) (Fig. 7A). These results indicate
that baseline SP-B production is largely independent of TACE activ-
ity, at least in MLE12 cells. MLE12 cells exposed to NRG alone
or NRG plus TAPI showed higher levels of SP-B protein. SP-B was sig-
niﬁcantly increased in NRG treated cells to 214% ± 14 (means ± SE,
n = 4, p = 0.0004) and in NRG plus TAPI treated cells to 197% ± 11
(means ± SE, n = 4, p = 0.004) (Fig. 7B). These results conﬁrm that
unlike PSEN-1, TACE is not involved in NRG-stimulated mediation of
ErbB4 control of SP-B expression in MLE12 cells. Analysis of the
conditioned media showed that TAPI-treated cells shed signiﬁcantly
less ErbB4 ectodomain (50% ± 3.4; mean ± SE, n = 4, p = 0.001)
compared to untreated cells. NRG treatment stimulated ectodomain
release in control cells (143.8% ± 5; mean ± SE, n = 4, p = 0.01).
As expected, this stimulatory effect was absent in conditioned
media from TAPI treated cells (Fig. 8A). The presence of the 4ICD
fragment in cell lysates from TAPI treated cells was not changed
(85.3% ± 5.8; mean ± SE, n = 3, p = 0.17) compared to media
treated cells (Fig. 8B). These data indicate that TACE inhibition by
TAPI prevents TACE activity consistent with TACE knockdown using
siRNA.
Fig. 6. The effect of TACE knockdown on the levels of the 4ICD cleavage fragment (A) and
the released ectodomain fragment (B) inMLE-12 cells. Figure shows representative west-
ern blots and densitometry values normalized to SCRwithout or with NRG treatments re-
spectively. Bars aremeans ± SEM of N= 4 experiments; **= P b 0.005 compared to SCR
condition, T-test with Bonferroni correction for multiple comparisons.
Fig. 7. The effect of TACE inhibition by TAPI on SP-B levels. (A) Representativewestern blot
and densitometry quantiﬁcation of SP-B protein levels inMLE12 cells treated as control or
with 200 nMTAPI. Inhibition of TACE by TAPI did not affect SP-B levels. (B) Representative
western blot and densitometry quantiﬁcation of the effect of TACE inhibition by TAPI on
NRG stimulation of SPB protein levels. Bars represent mean± SEM of N= 4 experiments;
** = P b 0.005, *** = P b 0.0005 compared to the respective controls.
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In spite of advances in the treatment and prevention of RDS, includ-
ing the use of prenatal glucocorticoids and neonatal treatment with
postnatal surfactant replacement, RDS remains one of the signiﬁcant
causes of morbidity and mortality in premature infants [26,27]. There-
fore, it is important to investigate the endogenous pathways regulating
the control of surfactant synthesis in the alveolar type II cell. We have
shown the important role of ErbB4 receptor and its ligand NRG in sur-
factant synthesis [7,4,5,22], but the speciﬁc signaling mechanism(s) in
type II cells that promote surfactant synthesis is not well understood.
Our previous work suggests that ErbB4 proteolytic processing and traf-
ﬁcking mechanisms are involved in its control of type II cell maturation
and surfactant production [22]. In this study we deﬁned the signiﬁ-
cance of ErbB4 processing by PSEN-1 and TACE for stimulation of
type II cell surfactant DSPC synthesis and SP-B and SP-C expression
to provide a basis for the development of novel therapeutic ap-
proaches to prevent and treat RDS. In the process we found that pro-
teolytic processing of ErbB4 by PSEN-1 does not require previous
processing by TACE. These are novel ﬁndings for both ErbB4 signal-
ing and type II cell biology.
Previous studies of the proteolytic processing of ErbB4 in NRG-
induced signaling indicate this is a two step process beginning with
cleavage at the cell surface by TACE with shedding of the ectodomain,
followed by cleavage at the inner cell membrane by γ-secretase to re-
lease the 4ICD fragment which trafﬁcs to the nucleus [12]. There are
two separate enzymes that may make up the active component in the
γ-secretase complex, PSEN-1 and PSEN-2, which are transcribed from
different genes. While there is some overlap in their function, studies
show that γ-secretase complexes containing PSEN-1 or PSEN-2 have
functionally distinct phenotypes [20]. However, deletion of eitherPSEN-1 or PSEN-2 in mice results in pulmonary phenotypes [23].
While the pulmonary phenotypes have not been completely character-
ized, it is known that newborn mice with PSEN-1 knockout have lungs
with poorly developed saccular structures and undergo neonatal
death with poorly expanded lungs. PSEN-2 knockout mice survive
birth but develop progressive alveolar wall thickening, alveolar and air-
way ﬁbrosis, and hemorrhage. Double knockouts show an exacerbation
of the fetal/neonatal abnormalities of alveolar development [20,21].
Mice with an inactivatingmutation in TACE also have poorly developed
saccular structures and undergo neonatal death with poorly expanded
lungs [28]. However, no study has addressed the interdependence of
TACE and PSEN-1 processing of ErbB4 in the ErbB4 signaling pathway
controlling type II cell surfactant expression.
We focused on PSEN-1 because of the more severe developmental
phenotype of alveolar maturation in the PSEN-1 knockout mouse. We
used siRNA to silence PSEN-1 expression in MLE12 cells. MLE12 cells
treated with siRNA targeting PSEN-1 showed a reduction in the level
of ErbB4 4ICD cytoplasmic cleavage product and no change in the
ectodomain shedding component of ErbB4.Moreover, these cells exhib-
ited signiﬁcant decreases in the surfactant proteins SP-B and SP-C and in
the synthesis of themajor phospholipid component of surfactant, DSPC.
Further, cells treated with PSEN-1 siRNA showed a reduction in the re-
leased ErbB4 4ICD cytoplasmic cleavage product and no change in the
shedding of the ectodomain component of ErbB4. NRG treatment
afforded the opportunity to evaluate the initiation of this ErbB4 process-
ing pathway. Our data indicate that cells treated with NRG showed in-
creased 4ICD levels in association with stimulated expression of SP-B,
SP-C and DSPC synthesis. The fact that these stimulatory effects were
lost with PSEN-1 knockdown provides important evidence of the im-
portance of PSEN-1 processing in ErbB4-mediated type II cell surfactant
synthesis that strengthens our conclusions from previous studies [22].
Thus our data indicate that ErbB4 signaling in lung alveolar type II
Fig. 8. The effect of TACE inhibition by TAPI on the levels of released ectodomain fragment (A) and 4ICD cleavage fragment (B) from ErbB4. Figure shows representative western blots and
densitometry values normalized to SCRwithout or with NRG treatments respectively. Bars are means± SEM of N= 4 experiments; * = P b 0.05, **= P= 0.005 compared to respective
controls. Bars are means ± SEM of N = 4 experiments.
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lytic cleavage for promoting surfactant synthesis.
In our studies of 4ICD levels in response to NRG treatment following
PSEN-1 knockdown, the effect of NRG stimulation on the level of 4ICD
was not completely removed. This could reﬂect some cleavage activity
by PSEN-2 or possibly the fact thatwith our knockdown thePSEN-1 pro-
tein level was reduced to 50%, possibly allowing a low residual PSEN-1
activity. However at the same time the NRG effect on the levels of SPB,
SPC and DSPC were all signiﬁcantly affected by the PSEN-1 knockdown.
This fact, plus the fact that the change in 4ICD with NRG was small, we
interpret as evidence that any residual 4ICD production was not sufﬁ-
cient to allow NRG stimulation of surfactant proteins and DSPC. This
conclusion is also supported by our previous work in which a mutant
ErbB4 construct that lacked a gamma secretase binding site transfected
into fetal lung type II cells did not increase baseline or NRG-stimulated
SP-B mRNA expression [22].
γ-Secretase cleavage and nuclear transport of ErbB4 are important
components in regulation of fetal lung type II cell surfactant protein pro-
duction [22]. Because the accepted model of ErbB4 proteolytic process-
ing includes cleavage by TACE followed by cleavage by γ-secretase, we
then sought to demonstrate that shedding of the ectodomain through
TACE cleavage is also a necessary ﬁrst step for ErbB4 signaling in con-
trolling surfactant synthesis. We used both siRNA to knock down TACE
and chemical inhibition of TACE enzyme activity in MLE12 cells to
study the importance of TACE processing of ErbB4 for SP-B and SP-C
production. For TACE inhibition we used TAPI, a hydroxamate inhibitor
of TACE activity [29], which targets the zinc activemotif on the enzyme.The results of these experiments showed that knockdown of TACE ei-
ther by siRNA or TAPI does not inhibit SP-B and SP-C expression in
MLE12 cells. More signiﬁcantly we found that TACE inhibition did not
suppress the stimulatory effect of NRG on surfactant protein levels. To
further probe the role of TACE we studied the effect of TACE inhibition
on γ-secretase mediated cleavage of ErbB4 in response to NRG by prob-
ing for the 4ICD fragment of ErbB4 in whole cell lysates of TACE siRNA
treated and TAPI treated cells. We found that even after TACE knock-
down or inhibition NRG stimulation continued to increase 4ICD levels.
On the other hand the shedding of the ectodomain of ErbB4 was de-
creased in the conditioned media of these cells, as would be expected
with inactivation of TACE. These ﬁndings suggest that the two cleavage
steps in ErbB4 are not linked events that must both occur for ErbB4 pro-
cessing leading to signaling by the 4ICD component. However, we can-
not rule out the possibility that the low remaining TACE activity was
sufﬁcient to prime PSEN-1 cleavage. Nevertheless, together with our
previous studies of the signiﬁcance of nuclear localization of ErbB4 in
NRG-mediated control of type II cell differentiation [22] these data indi-
cate that in this system proteolytic processing by TACE and by γ-
secretase have separate functions for ErbB4 signaling. In conclusion
we ﬁnd that ErbB4 signaling in type II epithelial cells utilizes the path-
way of the PSEN-1-dependent γ-secretase proteolysis. Our results em-
phasize the importance of PSEN-1 for ErbB4 signaling in control of
alveolar type II cell differentiation. Our work also introduces novel in-
sight into the mechanism of ErbB4 cleavage processing to produce sig-
naling by the 4ICD component by showing that TACE activity is not a
necessary antecedent for γ-secretase cleavage of ErbB4 in the control
805N. Fiaturi et al. / Biochimica et Biophysica Acta 1843 (2014) 797–805of surfactant DSPC synthesis and SP-B and SP-C expression. This dissoci-
ation between TACE and γ-secretase processing of ErbB4 in lung type II
cells may have important translational impact as investigators seek to
modulate ErbB4 signaling. In particular, this study may provide signiﬁ-
cant clues for how to target ErbB4 biology in developing translational
approaches to beneﬁt babies with RDS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.015.
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